Status:
ACTIVE_NOT_RECRUITING
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
Lead Sponsor:
University of Wisconsin, Madison
Collaborating Sponsors:
Revive Therapeutics, Ltd.
Conditions:
Methamphetamine Use Disorder
Substance-Related Disorders
Eligibility:
All Genders
25-65 years
Phase:
PHASE1
Brief Summary
The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Partic...
Detailed Description
The objective of this study is to determine the safety of psilocybin in adult participants with MUD. Eligible participants will be adults with methamphetamine use disorder recruited from the communit...
Eligibility Criteria
Inclusion
- Diagnosis of methamphetamine use disorder
Exclusion
- Positive urine pregnancy at any time point during screening or study participation
- Inadequately treated hypertension, defined as 2 blood pressure readings, 10 minutes apart, of greater than 140/90 mmHg systolic/diastolic
- Current acute coronary syndrome or angina
- History of heart transplant or stroke
- Current use of and inability or unwillingness to taper off of medications that may interact with psilocybin
- Current insulin dependence, due to Type I or Type II diabetes
Key Trial Info
Start Date :
March 3 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT05322954
Start Date
March 3 2023
End Date
May 1 2026
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53705